The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 18, 2008, Pages 3151-3158

  Nakou, E S ^a   Filippatos, T D ^a   Kiortsis, D N ^a   Derdemezis, C S ^a   Tselepis, A D ^b   Mikhailidis, D P ^c   Elisaf, M S ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

cholesterol; ezetimibe; high density lipoprotein; lipoprotein associated phospholipase A2; orlistat; paraoxonase; subclasses; triglycerides

Indexed keywords

ANTIOBESITY AGENT; ARYLDIALKYLPHOSPHATASE; AZETIDINE DERIVATIVE; EZETIMIBE; HIGH DENSITY LIPOPROTEIN 2; HIGH DENSITY LIPOPROTEIN 3; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LACTONE; PHOSPHOLIPASE A2; TETRAHYDROLIPSTATIN;

ADULT; ARTICLE; BLOOD; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG COMBINATION; ENZYMOLOGY; FEMALE; HUMAN; HYPERLIPIDEMIA; LOW FAT DIET; MALE; METABOLISM; MIDDLE AGED; OBESITY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL; TIME; TREATMENT OUTCOME;

ADULT; ANTI-OBESITY AGENTS; ANTICHOLESTEREMIC AGENTS; ARYLDIALKYLPHOSPHATASE; AZETIDINES; BODY MASS INDEX; CHOLESTEROL, HDL; DIET, FAT-RESTRICTED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERLIPIDEMIAS; LACTONES; LINEAR MODELS; LIPOPROTEINS, HDL2; LIPOPROTEINS, HDL3; MALE; MIDDLE AGED; OBESITY; PHOSPHOLIPASES A2; TIME FACTORS; TREATMENT OUTCOME;

EID: 59449101190     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656560802548430     Document Type: Article

References (40)

1. Chapman MJ, Assmann G, Fruchart JC, et al. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid-a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 2004;20:1253-68
2. Kontush A, Chapman MJ. Antiatherogenic small, dense HDL-guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med 2006;3:144-53
3. Salonen JT, Salonen R, Seppanen K, et al. HDL, HDL2, and HDL3 subfractions, and the risk of acute myocardial infarction. A prospective population study in eastern Finnish men. Circulation 1991;84:129-39
4. Mueller O, Chang E, Deng D, et al. PROCAM Study: risk prediction for myocardial infarction using microfl uidic high-density lipoprotein (HDL) subfractionation is independent of HDL cholesterol. Clin Chem Lab Med 2008;46:490-8
5. Asztalos BF, Cupples LA, Demissie S, et al. High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 2004;24:2181-7
6. Florentin M, Liberopoulos EN, Wierzbicki AS, Mikhailidis DP. Multiple actions of high-density lipoprotein. Curr Opin Cardiol 2008;23:370-8
7. Link JJ, Rohatgi A, De Lemos JA. HDL cholesterol: physiology, pathophysiology and management. Curr Probl Cardiol 2007;32:268-314
8. TselepisAD, Chapman JM. Infl ammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atheroscler Suppl 2002;3:57-68
9. James RW. A long and winding road: defi ning the biological role and clinical importance of paraoxonases. Clin Chem Lab Med 2006;44:1052-9
10. Nakou ES, Filippatos TD, Georgoula M, et al. The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. Curr Med Res Opin 2008;24:1919-29
11. Saougos VG, Tambaki AP, Kalogirou M, et al. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler Thromb Vasc Biol 2007;27:2236-43
12. Filippatos TD, Liberopoulos EN, Kostapanos M, et al. The effects of orlistat and fenofi brate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome. Diabetes Obes Metab 2008;10:476-83
13. Tselepis AD, Dentan C, Karabina SA, et al. PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme. Arterioscler Thromb Vasc Biol 1995;15:1764-73
14. Tsimihodimos V, Karabina SA, Tambaki AP, et al. Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB. Arterioscler Thromb Vasc Biol 2002;22:306-11
15. Filippatos TD, Gazi IF, Liberopoulos EN, et al. The effect of orlistat and fenofi brate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis 2007;193:428-37
16. Tselepis AD, Goudevenos JA, Tambaki AP, et al. Platelet aggregatory response to platelet activating factor (PAF), ex vivo, and PAF-acetylhydrolase activity in patients with unstable angina: effect of c7E3 Fab (abciximab) therapy. Cardiovasc Res 1999;43:183-91
17. Sartorio A, Lafortuna CL, Vangeli V, et al. Short-term changes of cardiovascular risk factors after a non-pharmacological body weight reduction program. Eur J Clin Nutr 2001;55:865-9
18. Noakes M, Keogh JB, Foster PR, Clifton PM. Effect of an energy-restricted, high-protein, low-fat diet relative to a conventional high-carbohydrate, low-fat diet on weight loss, body composition, nutritional status, and markers of cardiovascular health in obese women. Am J Clin Nutr 2005;81:1298-306
19. Filippatos TD, Kiortsis DN, Liberopoulos EN, et al. Effect of orlistat, micronised fenofi brate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Curr Med Res Opin 2005;21:1997-2006
20. Kiortsis DN, Filippatos TD, Elisaf MS. The effects of orlistat on metabolic parameters and other cardiovascular risk factors. Diabetes Metab 2005;31:15-22
21. Mittendorfer B, Ostlund RE, Jr Patterson BW, Klein S. Orlistat inhibits dietary cholesterol absorption. Obes Res 2001;9:599-604
22. Von Eckardstein A, Nofer JR, Assmann G. High density lipoproteins and arteriosclerosis. Role of cholesterol effl ux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2001;21:13-27
23. Danielsen EM, Hansen GH, Poulsen MD. Apical secretion of apolipoproteins from enterocytes. J Cell Biol 1993;120:1347-56
24. Al Majali K, Cooper MB, Staels B, et al. The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modifi cation by lipases, and lipid transfer activities in type 2 diabetic patients. Diabetologia 2006;49:527-37
25. Davis HR, Veltri EP. Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia. J Atheroscler Thromb 2007;14:99-108
26. Huff MW, Pollex RL, Hegele RA. NPC1L1: evolution from pharmacological target to physiological sterol transporter. Arterioscler Thromb Vasc Biol 2006;26:2433-8
27. Sweeney ME, Johnson RR. Ezetimibe: an update on the mechanism of action, pharmacokinetics and recent clinical trials. Expert Opin Drug Metab Toxicol 2007;3:441-50
28. Fras Z, Mikhailidis DP. Statin plus ezetimibe treatment in clinical practice: the SI-SPECT (Slovenia (SI) Statin Plus Ezetimibe in Cholesterol Treatment) monitoring of clinical practice study. Curr Med Res Opin 2008;24:2467-76
29. Kalogirou M, Tsimihodimos V, Gazi I, et al. Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr Med Res Opin 2007;23:1169-76
30. Gazi IF, Daskalopoulou SS, Nair DR, Mikhailidis DP. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Curr Med Res Opin 2007;23:2183-92
31. Mikhailidis DP, Sibbring GC, Ballantyne CM, et al. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin 2007;23:2009-26
32. Ose L, Reyes R, Johnson-Levonas AO, et al. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques. Clin Ther 2007;29:2419-32
33. Asztalos BF, Collins D, Cupples LA, et al. Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol 2005;25:2185-91
34. Asztalos BF, Batista M, Horvath KV, et al. Change in alpha1 HDL concentration predicts progression in coronary artery stenosis. Arterioscler Thromb Vasc Biol 2003;23:847-52
35. Otvos JD, Collins D, Freedman DS, et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfi brozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 2006;113:1556-63
36. Elisaf M, Tselepis AD. Effect of hypolipidemic drugs on lipoprotein-associated platelet activating factor acetylhydrolase. Implication for atherosclerosis. Biochem Pharmacol 2003;66:2069-73
37. Mackness MI, Mackness B, Durrington PN, et al. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Curr Opin Lipidol 1996;7:69-76
38. Mackness MI, Mackness B, Durrington PN. Paraoxonase and coronary heart disease. Atheroscler Suppl 2002;3:49-55
39. Mackness MI, Arrol S, Abbott C, Durrington PN. Protection of low-density lipoprotein against oxidative modifi cation by high-density lipoprotein associated paraoxonase. Atherosclerosis 1993;104:129-35
40. Audikovszky M, Pados G, Seres I, et al. Orlistat increases serum paraoxonase activity in obese patients. Nutr Metab Cardiovasc Dis 2007;17:268-73